The changes in cardiovascular prevention practice between 1995 and 2012 in the Czech Republic. A comparison of EUROASPIRE I, II, III and IV study

Mayer, Otto; Bruthans, Jan; Timoracká, Katarína

doi:10.1016/j.crvasa.2014.01.008

Cited by 12 publications

(8 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most remarkable progress throughout the EUROASPIRE studies has been achieved in the control of hypercholesterolemia. 6,7 Mean levels of total and LDL cholesterol further decreased in the present study. The decrease in cholesterol levels was a major factor behind the decrease in the CHD mortality in the Czech Republic.…”

Section: Discussionsupporting

confidence: 55%

“…The survey was performed in compliance with the EUROASPIRE V study protocol, copying previous EUROASPIRE study protocols, described in detail elsewhere. [4][5][6][7] At interview, each respondent's history was taken including their personal and demographic characteristics, personal and family history of cardiovascular disease, data on adherence to principles of a healthy lifestyle, and pharmacotherapy. Standardized measurements were made as per protocol using calibrated devices, with blood sampling and patients completing the self-reported questionnaires in the respective validated national form.…”

Section: Data Collectionmentioning

confidence: 99%

“…The Czech Republic, with its two study centers (Prague and Pilsen), has participated in all fi ve surveys; results of the fi rst four surveys were published showing both European and, separately, Czech data. [4][5][6][7]…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Current status of secondary prevention in Czech coronary patients in the EUROASPIRE V Study

Bruthans¹,

Mayer²,

Šulc³

et al. 2019

Cor Vasa

Self Cite

View full text Add to dashboard Cite

Sekundární kardiovaskulární (KV) prevence po prodělaném infarktu myokardu (IM) je neméně důležitá než léčba akutního IM. Lepší KV prevence může rozhodující měrou přispět k pokračování pozitivních trendů KV morbidity a mortality v České republice v posledních třech desetiletích. Cíl: Stanovit, jak jsou do praxe implementována nedávná evropská doporučení pro sekundární prevenci ischemické choroby srdeční (ICHS) (2012). Metodika: Konsekutivně a retrospektivně bylo vybráno 624 pacientů, mužů a žen ve věku ≤ 80 let, hospitalizovaných pro akutní koronární syndrom a/nebo chirurgickou či katetrizační koronární revaskularizaci. Byl proveden rozbor chorobopisů a následně byli ambulantně vyšetřeni respondenti, minimálně šest měsíců, maximálně dva roky po přijetí k hospitalizaci. Výsledky: Celkem bylo vyšetřeno 406 respondentů. Z nich 20 % byli aktivní kuřáci, 44,8 % bylo obézních (BMI ≥ 30), v pásmu nadváhy a obezity (BMI ≥ 25) bylo 85,5 % respondentů, centrálně obézních (obvod pasu ≥ 102 cm u mužů, ≥ 88 cm u žen) 70,2 %, doporučované fyzické aktivity (30 minut 5× týdně) nedosáhlo 85 %. Krevní tlak zvýšený nad hodnoty požadované v doporučeních kardiovaskulární prevence z roku 2012 (≥ 140/90 mm Hg, u diabetiků ≥ 140/80 mm Hg) mělo 55,1 % pacientů, zvýšený LDL-cholesterol (≥ 1,8 mmol/l) 63,5 % pacientů. Diabetes (známý a nově diagnostikovaný) vykazovalo 41,2 % respondentů, prediabetes 23,4 %. Při použití glukózového tolerančního testu to bylo 44,7 %, respektive 32,3 %. V době našeho vyšetření bylo 88,4 % pacientů léčeno antiagregancii, 81,3 % beta-blokátorem, 78,8 % inhibitory angiotenzin konvertujícího enzymu (ACEI) nebo antagonistou receptoru ATII, 92,1 % statinem, 92,9 % prodělalo koronární revaskularizaci. Závěr: Většina pacientů v sekundární prevenci ICHS má nezdravý životní styl-nezdravou dietu a nedostatečnou pohybovou aktivitu. Prevalence nadváhy, obezity a diabetu je velmi vysoká, prevalence obezity a centrální obezity se dále zvýšila. Farmakoterapie je v sekundární prevenci používána u většiny pacientů, ale doporučených hodnot krevního tlaku, lipidového a glycidového metabolismu je dosahováno jen u menšiny.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Data Collectionmentioning

confidence: 99%

See 1 more Smart Citation

Current status of secondary prevention in Czech coronary patients in the EUROASPIRE V Study

Bruthans¹,

Mayer²,

Šulc³

et al. 2019

Cor Vasa

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, patients with impaired fasting glycemia had comparable mortality risk as patients with overt diabetes mellitus. It is also necessary to stress that impaired fasting glycemia is highly prevalent condition in CHD patients (one quarter of patients in our sample) with evident increase over time in last 20 years [17].…”

Section: Discussionmentioning

confidence: 96%

The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients

Slezák

Mayer

Bruthans

et al. 2018

Exp Clin Endocrinol Diabetes

Self Cite

View full text Add to dashboard Cite

show abstract

“…There were 36% of regular smokers among men and 22% among women in our survey, while the corresponding numbers in the general population were 30% for men and 19% for women. This finding does not seem to be surprising as investigators of the EUROASPIRE studies have failed to document any significant decreases of smoking in the cohorts of patients with established diagnosis of coronary artery disease (9).…”

Section: Discussionmentioning

confidence: 87%

Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic

Chmelík¹,

Vaclová²,

Lánská³

et al. 2020

Cent Eur J Public Health

View full text Add to dashboard Cite

Objective: The aim of this analysis was to analyze the presence of the most important cardiovascular (CV) risk factors and to discuss patterns of LDL cholesterol management in the population studied. Methods: We enrolled 961 males, average age of 42.9 ± 4.7, and 851 females, average age of 51.2 ± 3.6. Data on personal, pharmacological and family history, and laboratory examinations were collected. Cardiovascular (CV) risk was calculated using the Systematic Coronary Risk Evaluation (SCORE) algorithm with modifications according to the guidelines. Results: The distribution of CV risk in the observed cohort was as follows: 24% of the subjects had low, 51% moderate, 17% high and 8% very high risk. The percentage of patients who reached target values of LDL cholesterol was dramatically lower in the groups with very high (1%) and high (3%) risk than in the groups with moderate (14%) or low risk (59%). Dyslipidemia was newly identified in 20% of both sexes. Arterial hypertension was newly diagnosed in 8% of males and 5% of females, and type 2 diabetes mellitus was newly diagnosed in 3% of both the males and females. Dyslipidemia was present in 39% of males and 41% of females; arterial hypertension in 43% of males and 45% of females, and type 2 diabetes mellitus was diagnosed in 11% of the subjects of both sexes. 49% of males and 31% of females were overweight and 32% of both genders were obese. There were 36% of male smokers and 22% of female smokers. 48% of the participants were pharmacologically treated. Non-pharmacological treatment was recommended to 62% of male and to 65% of female participants. Pharmacological intervention was started in 53% of males and 51% of females. In both gender antihypertensive treatment with angiotensin-converting enzyme (ACE) inhibitors (29% of males and 27% of females) and lipid lowering therapy with a statin (28% of males, 27% of females) were the most commonly initiated treatments. In the subgroup of the 101 patients with LDL cholesterol levels > 5 mmol/L 56% were not treated with a statin. The analysis of relationship between the positive family history of any of the followed CV risks showed significant increases of the risk for arterial hypertension, type 2 diabetes mellitus and dyslipidemia. Conclusion: European guidelines suggest general screening for risk factors, including analysis of lipid profiles in the population of 40-year-old males and 50-year-old or postmenopausal women. Our study documents high prevalence and incidence of CV risk factors together with insufficient control of the risk factors in Czech patients of this age range. This finding suggests that preventive examinations should be undertaken earlier (e.g., in 30-year-old males and 40-year-old women). Exact timing of the preventive checkups to yield the best cost-benefit ratio needs to be verified.

show abstract

The changes in cardiovascular prevention practice between 1995 and 2012 in the Czech Republic. A comparison of EUROASPIRE I, II, III and IV study

Cited by 12 publications

References 14 publications

Current status of secondary prevention in Czech coronary patients in the EUROASPIRE V Study

Current status of secondary prevention in Czech coronary patients in the EUROASPIRE V Study

The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients

Analysis of incidence and prevalence of cardiovascular risk factors and evaluation of their control in epidemiological survey in the Czech Republic

Contact Info

Product

Resources

About